BidaskClub downgraded shares of Medidata Solutions (NASDAQ:MDSO) from a buy rating to a hold rating in a report published on Tuesday, BidAskClub reports.

MDSO has been the topic of a number of other research reports. Wells Fargo & Co reiterated a hold rating on shares of Medidata Solutions in a research report on Thursday, June 13th. SunTrust Banks lifted their target price on Medidata Solutions from $85.00 to $92.25 and gave the company a hold rating in a research report on Thursday, June 13th. JPMorgan Chase & Co. upgraded Medidata Solutions from an underweight rating to a neutral rating in a research report on Wednesday, June 12th. Dougherty & Co lowered Medidata Solutions from a buy rating to a neutral rating in a research note on Wednesday, May 1st. Finally, William Blair lowered Medidata Solutions from an outperform rating to a market perform rating in a research note on Wednesday, June 12th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the stock. Medidata Solutions has a consensus rating of Hold and a consensus price target of $84.27.

Shares of NASDAQ MDSO opened at $91.61 on Tuesday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.56 and a current ratio of 2.56. Medidata Solutions has a 52 week low of $60.10 and a 52 week high of $98.60. The stock has a market capitalization of $5.72 billion, a P/E ratio of 95.43, a PEG ratio of 6.05 and a beta of 1.23. The stock’s fifty day moving average is $91.14 and its 200 day moving average is $84.91.

Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings results on Monday, July 22nd. The company reported $0.48 EPS for the quarter, topping the Zacks’ consensus estimate of $0.17 by $0.31. Medidata Solutions had a return on equity of 8.64% and a net margin of 6.43%. The company had revenue of $180.50 million for the quarter, compared to analysts’ expectations of $179.95 million. During the same quarter last year, the business earned $0.43 earnings per share. Medidata Solutions’s revenue was up 15.8% on a year-over-year basis. Equities research analysts forecast that Medidata Solutions will post 0.78 earnings per share for the current year.

In other news, Director Robert Taylor sold 3,294 shares of Medidata Solutions stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $90.88, for a total transaction of $299,358.72. Following the sale, the director now directly owns 41,757 shares of the company’s stock, valued at $3,794,876.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.70% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Quadrant Capital Group LLC lifted its stake in shares of Medidata Solutions by 126.8% in the first quarter. Quadrant Capital Group LLC now owns 592 shares of the company’s stock worth $40,000 after acquiring an additional 331 shares during the period. Flagship Harbor Advisors LLC lifted its stake in Medidata Solutions by 58.3% in the second quarter. Flagship Harbor Advisors LLC now owns 475 shares of the company’s stock valued at $42,000 after buying an additional 175 shares during the period. FTB Advisors Inc. lifted its stake in Medidata Solutions by 212.4% in the second quarter. FTB Advisors Inc. now owns 934 shares of the company’s stock valued at $84,000 after buying an additional 635 shares during the period. Tower Research Capital LLC TRC lifted its stake in Medidata Solutions by 102.0% in the second quarter. Tower Research Capital LLC TRC now owns 1,697 shares of the company’s stock valued at $153,000 after buying an additional 857 shares during the period. Finally, Meeder Asset Management Inc. acquired a new position in Medidata Solutions in the second quarter valued at approximately $185,000. 91.15% of the stock is currently owned by institutional investors.

Medidata Solutions Company Profile

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.

Read More: How is the discount rate different from the Federal Funds rate?

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.